Statement of Ownership (sc 13g)
April 21 2017 - 2:53PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934 (Amendment No. __N/A__)*
PTC
Therapeutics, Inc.
(Name
of Issuer)
Common
Stock
(Title
of Class of Securities)
69366J200
(CUSIP
Number)
April
11, 2017
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ]
Rule 13d-1(b)
[X]
Rule 13d-1(c)
[ ]
Rule 13d-1(d)
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.
The
informat
i
on re
q
u
ired
in the remai
n
der of
t
h
is
cover
p
age s
h
all not
b
e
d
eemed to
b
e “file
d
”
f
o
r
t
h
e
purpose of Secti
o
n 18 of
t
h
e
Securities
E
x
change Act of 1934 (
“
Act”)
or ot
h
erw
i
se su
b
ject
to t
h
e l
i
abil
i
ties
of t
h
at sect
i
on of
t
h
e
Act b
u
t s
h
all be subject
t
o
a
l
l o
t
her
prov
i
s
i
ons of t
h
e
Act (h
o
w
eve
r
,
see the N
o
tes).
C
U
S
IP
N
o
.
69366J200
1.
|
NAME
OF REPORTING PERSONS
|
|
|
I.R.S.
IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
|
|
|
|
|
|
RTW
Investments, LP
|
|
|
|
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
|
|
|
|
(a)
[ ]
|
|
|
(b)
[X]
|
3.
|
SEC
USE ONLY
|
|
|
|
|
|
|
|
4.
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
|
|
|
|
|
|
Delaware
|
|
|
|
|
NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
|
|
|
|
5.
|
SOLE
VOTING POWER
|
|
|
|
|
|
0
|
|
|
|
|
6.
|
SHARED
VOTING POWER
|
|
|
|
|
|
1,794,336*
|
|
|
|
|
7.
|
SOLE
DISPOSITIVE POWER
|
|
|
|
|
|
0
|
|
|
|
|
8.
|
SHARED
DISPOSITIVE POWER
|
|
|
|
|
|
1,794,336*
|
|
|
|
|
9.
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
1,794,336*
|
|
|
|
|
10.
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
[ ]
|
|
|
|
11.
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
5.2%*
|
|
|
|
|
12.
|
TYPE
OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
IA,
PN
|
|
C
U
S
IP
N
o
.
69366J200
1.
|
NAME
OF REPORTING PERSONS
|
|
|
I.R.S.
IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
|
|
|
|
|
|
Roderick
Wong
|
|
|
|
|
2.
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
|
|
|
|
(a)
[ ]
|
|
|
(b)
[X]
|
3.
|
SEC
USE ONLY
|
|
|
|
|
|
|
|
4.
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
|
|
|
|
|
|
United
States of America
|
|
|
|
|
NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
|
|
|
|
5.
|
SOLE
VOTING POWER
|
|
|
|
|
|
0
|
|
|
|
|
6.
|
SHARED
VOTING POWER
|
|
|
|
|
|
1,794,336*
|
|
|
|
|
7.
|
SOLE
DISPOSITIVE POWER
|
|
|
|
|
|
0
|
|
|
|
|
8.
|
SHARED
DISPOSITIVE POWER
|
|
|
|
|
|
1,794,336*
|
|
|
|
|
9.
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
1,794,336*
|
|
|
|
|
10.
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
[ ]
|
|
|
|
11.
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
5.2%*
|
|
|
|
|
12.
|
TYPE
OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
IN,
HC
|
|
Item
1.
|
(a).
|
Name
of Issuer:
PTC
Therapeutics, Inc.
|
|
|
|
|
(b).
|
Address
of issuer’s principal executive offices:
|
|
|
|
|
|
100
Corporate Court
|
|
|
|
|
|
South
Plainfield, NJ 07080-2449
|
|
|
|
Item
2.
|
(a).
|
Name
of person filing:
|
|
|
|
|
|
RTW
In
v
e
s
t
me
n
t
s
,
LP
|
|
|
Roderick
W
o
n
g
|
|
(b).
|
Address
or principal business office or, if none, residence:
|
|
|
|
|
|
R
TW
In
v
e
s
t
me
n
t
s
,
LP
250
W
est 5
5
th Street,
1
6
th
Floor
|
|
|
Suite
A
|
|
|
New
York, New York 10019
|
|
|
|
|
|
Roder
i
ck
W
o
n
g
|
|
|
|
|
|
c
/
o
R
TW I
n
vestme
n
ts,
LP
250
W
est 5
5
th Street,
1
6
th
Floor
|
|
|
S
u
ite
A
|
|
|
New
Y
or
k
,
N
e
w
Y
o
r
k
1
0
01
9
|
|
(c).
|
Citizenship:
|
|
|
|
|
|
RTW
In
v
e
s
t
me
n
t
s
,
LP
–
Dela
wa
re
|
|
|
Roderick
W
o
ng – United States of America
|
|
|
|
|
(d).
|
Title
of class of securities:
|
|
|
Common
Stock, $0.001 par value per share
|
|
|
|
|
(e).
|
CUSIP
No.:
|
|
|
|
|
|
69366J200
|
|
|
|
C
U
S
IP
N
o
.
69366J200
Item
3.
|
If
This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is
a
|
|
|
|
N/A
|
|
|
Item
4.
|
Ownership.
|
|
|
|
Provide
the following information regarding the aggregate number and percentage of the class
of securities of the issuer identified in Item 1.
|
|
(a)
|
Amount
beneficially owned:
|
|
|
|
|
|
R
TW
Investments, LP – 1,794,336*
|
|
|
Roderick
W
ong – 1,794,336*
|
|
(b)
|
Percent
of class:
|
|
|
|
|
|
R
TW
Investments, LP –
5.2%
*
|
|
|
Roderick
Wong – 5.2%*
|
|
(c)
Number of shares as to which the person has:
|
|
|
|
|
|
|
(i)
|
Sole
power to vote or to direct the vote
|
|
|
|
|
|
|
|
RTW
Investments, LP – 0
|
|
|
|
Roderick
Wong – 0
|
|
|
|
|
|
|
(ii)
|
Shared
power to vote or to direct the vote
|
|
|
|
|
|
|
|
R
TW
Investments, LP – 1,794,336*
|
|
|
|
Roderick
W
ong – 1,794,336*
|
|
|
|
|
|
|
(iii)
|
Sole
power to dispose or to direct the disposition of
|
|
|
|
|
|
|
|
R
TW
Investments, LP – 0
|
|
|
|
Roderick
W
ong – 0
|
|
|
|
|
|
|
(iv)
|
Shared
power to dispose or to direct the disposition of
|
|
|
|
|
|
|
|
R
TW
Investments, LP – 1,794,336*
|
|
|
|
Roderick
W
ong – 1,794,336*
|
*
The shares of common stock, $.001 par value (the “Shares”), of PTC Therapeutics, Inc. (the “Company”)
reported herein are held by one or more private funds (together the “Funds”) managed by RTW Investments, LP (the “Adviser”).
The Adviser, in its capacity as the investment manager of the Funds, has the power to vote and the power to direct the disposition
of all Shares held by the Funds. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially
own an aggregate of 1,794,336 Shares, or 5.2% of the Company’s 34,556,440 shares of common stock deemed issued and outstanding
as of February 24, 2017, as disclosed in the Company’s Annual Form 10-K filed with the Securities and Exchange Commission
on March 16, 2017. Roderick Wong is the Managing Partner of the Adviser. This report shall not be deemed an admission that the
Adviser, the Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of
the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the reporting persons herein disclaims beneficial
ownership of the Shares reported herein except to the extent of the reporting person’s pecuniary interest therein.
C
U
S
IP
N
o
.
69366J200
Item
5.
|
Ownership
of Five Percent or Less of a Class.
|
|
|
|
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following [ ].
|
|
|
|
N/A
|
|
|
Item
6.
|
Ownership
of More Than Five Percent on Behalf of Another Person.
|
|
|
|
If
any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds
from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest
relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment
company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or
endowment fund is not required.
|
|
|
|
N/A
|
|
|
Item
7.
|
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control
Person.
|
|
|
|
If
a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under
Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent
holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating
the identification of the relevant subsidiary.
|
|
|
|
N/A
|
|
|
Item
8.
|
Identification
and Classification of Members of the Group.
|
|
|
|
If
a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit
stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to
Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
|
|
|
|
N/A
|
|
|
Item
9.
|
Notice
of Dissolution of Group.
|
|
|
|
Notice
of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings
with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual
capacity. See Item 5.
|
|
|
|
N/A
|
|
|
Item
10.
|
Certification.
|
|
|
|
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and
are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities
and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated:
April 21, 2017
|
RTW
Investments, LP
|
|
|
|
|
By:
|
/s/
Roderick Wong
|
|
|
Roderick
Wong, Managing Partner
|
|
|
|
|
Roderick
Wong
|
|
|
|
|
By:
|
/s/
Roderick Wong
|
|
|
Roderick
Wong, Individually
|
The
original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If
the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner
of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the
statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated
by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
Note.
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7
for other parties for whom copies are to be
sent.
Attention.
Intentional misstatements or omissions of fact constitute Federal criminal violations
(see 18 U.S.C. 1001).
PTC Therapeutics (NASDAQ:PTCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
PTC Therapeutics (NASDAQ:PTCT)
Historical Stock Chart
From Apr 2023 to Apr 2024